Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dexcom ( (DXCM) ) has issued an update.
Dexcom’s board has confirmed that President and Chief Operating Officer Jacob S. Leach will assume the roles of President, Chief Executive Officer and director effective January 1, 2026, following the previously announced resignation of long-time CEO Kevin R. Sayer as of that date. On December 19, 2025, Leach agreed to an offer package that includes a $1,150,000 annual base salary, a target annual bonus equal to 150% of base pay, $7.5 million in time-vested restricted stock units over three years, and $7.5 million in performance stock units contingent on meeting compensation committee–set performance goals, while remaining eligible for existing executive severance and benefit plans; the board expects Sayer to return from medical leave around March 2026 to resume his role as board chairman, with Mark Foletta serving as interim chair in the meantime, signaling continuity in the company’s leadership transition and governance structure.
The most recent analyst rating on (DXCM) stock is a Buy with a $78.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
Dexcom’s overall stock score reflects its strong financial performance and positive earnings call sentiment, which are the most significant factors. The stock’s technical indicators suggest bullish momentum, but caution is advised due to potential overbought conditions. Valuation remains a concern with a high P/E ratio, and recent corporate events bolster long-term strategic positioning.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
Dexcom, Inc. is a medical technology company specializing in continuous glucose monitoring systems for people with diabetes, providing real-time glucose data to patients and healthcare providers and focusing on the broader diabetes management market.
Average Trading Volume: 6,261,966
Technical Sentiment Signal: Strong Sell
Current Market Cap: $25.76B
Learn more about DXCM stock on TipRanks’ Stock Analysis page.